Featured Research

from universities, journals, and other organizations

Gene signature may improve colon cancer treatment

Date:

February 27, 2010

Source:

Vanderbilt University Medical Center

Summary:

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study. The findings could help personalize treatments for colon cancer -- the second leading cause of cancer-related deaths in the United States -- by identifying patients most likely to benefit from chemotherapy.

Share This

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

Related Articles

The findings, published in the March issue of Gastroenterology, could help personalize treatments for colon cancer -- the second leading cause of cancer-related deaths in the United States -- by identifying patients most likely to benefit from chemotherapy.

In its early stages, colorectal cancer is treated with surgery only. However, between 20 percent and 25 percent of patients with Stage II disease (when the tumor has penetrated the muscular wall of the colon) will experience metastatic recurrence after surgical resection alone.

For stage III, when the cancer has spread to the lymph nodes, surgery is generally followed by chemotherapy -- despite research showing that about 40 percent of stage III patients treated by surgery alone do not have a recurrence of disease in five years.

This suggests that identifying stage II patients at the greatest risk for recurrence -- and targeting adjuvant chemotherapy to them -- could decrease recurrences in that group. In addition, those stage III patients at lowest risk, if prospectively identified, could avoid having potentially toxic chemotherapy.

Using a mouse colon cancer cell line, R. Daniel Beauchamp, M.D., the John Clinton Foshee Distinguished Professor of Surgery and chair of the Section of Surgical Sciences, and colleagues identified 300 genes that showed distinct patterns of expression related to their ability to invade into a gel-like matrix, a test that reflects the aggressiveness of cancer cells.

Statistical analysis, led by Yu Shyr, Ph.D., the Ingram Professor of Cancer Research and professor of Biostatistics, helped refine the initial set of 300 genes into a set of 34 genes that were most closely associated with metastasis and death in a set of human colon cancer samples from Vanderbilt patients.

The researchers then examined whether this 34-gene signature could predict recurrence and death in a larger patient population.

In colon cancer tissue samples from 177 patients from the H. Lee Moffitt Cancer Center in Tampa, Fla., the signature identified in the highly invasive mouse cells -- the "high recurrence" (or "poor prognosis") signature -- was associated with increased risk of recurrence and death across all stages of disease.

Among patients with stage II disease, those with the "poor prognosis" signature had a five-year mortality rate of 31 percent. However, no stage II patients with a "low recurrence" (or "good prognosis") signature died within the five-year period.

In patients with stage III disease, 38 percent of those with a "poor" signature died of their disease within five years, whereas only 10.7 percent of those with a "good" prognosis signature died within that time period.

"Across all stages, if patients had a 'poor' prognosis signature, then they would be five times more likely to have a recurrence of cancer than those with a 'good' prognosis signature," said Beauchamp.

But the most interesting finding, Beauchamp says, is the ability of this gene signature to identify the patients most likely to benefit from chemotherapy.

Among stage III patients with a "poor" prognosis signature, those who had received chemotherapy had a 36 percent cancer-related death rate. Those who did not receive chemotherapy had an 86 percent death rate.

"That tells us that patients with the ('poor' prognosis signature) probably benefited from chemotherapy," Beauchamp said. "And (patients with a 'good' prognosis signature) appeared to get no benefit from chemotherapy."

"This really feeds right into personalized cancer medicine…in identifying subgroups of patients that will benefit from one treatment versus another treatment modality, trying to target those patients that are most likely to benefit…and not exposing patients who are less likely to benefit with potentially toxic treatments," Beauchamp said.

"Ultimately this should lead to more individualized therapy for cancer patients."

The research was supported by grants from National Institutes of Health.

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 31, 2015  Fewer than half of the physicians trained in the United States in 2013 received formal education or training on the subject of exercise, according to new research. "There are immense medical benefits ... full story

Mar. 31, 2015  Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, researchers report. "With this treatment, cells under ... full story

Mar. 31, 2015  Increasing state alcohol taxes could prevent thousands of deaths a year from car crashes, say researchers, who found alcohol-related motor vehicle crashes decreased after taxes on beer, wine and ... full story

Mar. 31, 2015  Alcoholism takes a toll on every aspect of a person's life, including skin problems. Now, a new research report helps explain why this happens and what might be done to address it. "The clinical ... full story

Mar. 31, 2015  A new population of 'memory' immune cells has been discovered by scientists, throwing light on what the body does when it sees a microbe for the second time. This insight, and others like it, will ... full story

Mar. 31, 2015  Coronary heart disease and stroke, two of the leading causes of death in the United States, are diseases associated with heightened platelet reactivity. A new study in humans suggests an underlying ... full story

Mar. 31, 2015  A new study had researchers seeking answers to why the therapeutic benefit afforded by SSRIs was so limited in children and teenagers. If researchers can uncover the biological mechanisms preventing ... full story

Mar. 31, 2015  A drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present ... full story

Mar. 31, 2015  It is possible to quantify and classify the effects of different diseases on the activity of intestinal bacteria, new research demonstrates for the first time. Human intestinal flora, known as ... full story

Featured Videos

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015)  The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports.
Video provided by Reuters

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015)  Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17
Video provided by AFP

Related Stories

June 23, 2014  African-Americans with colon cancer are half as likely as Caucasian patients to have a type of colon cancer that is linked to better outcomes. The finding may provide insight into why ... full story

June 17, 2011  A compound that for about 60 years has been used as a drug against tapeworm infection is also apparently effective against colon cancer metastasis, as studies using mice have shown. The compound ... full story

May 7, 2010  A research team from China investigated the association between peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene polymorphism 34 C>G and colorectal cancer (CRC) through a ... full story

Apr. 21, 2010  Scientists are reporting an advance toward development of a urine test for detecting colon cancer, the third most common cancer in the United States. Such a test could eventually compliment or even ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.